Table 1:
Overview of included studies.
| Author | Year | Country | Study period | Study type | Total n |
Primary ovarian cancer (%) | Recurrent ovarian cancer (%) | Intervention | MINORS score | |
|---|---|---|---|---|---|---|---|---|---|---|
| Primary ovarian cancer | Recurrent ovarian cancer | |||||||||
| Park [16] | 2006 | Korea | 2001–2005 | Retrospective cohort study | 60 | 46 (76.7) | 14 (23.3) | PRCS+HIPEC | SCRS+HIPEC | 15 |
| Rufián [17] | 2006 | Spain | 1997–2004 | Retrospective cohort study | 33 | 19 (57.6) | 14 (42.4) | PRCS+HIPEC | SCRS+HIPEC | 15 |
| Di Giorgio A [18] | 2008 | Italy | 2000–2007 | Non randomized phase 2 study, open, prospective | 47 | 22 (46.8) | 25 (53.2) | PRCS HIPEC: Cisplatin+doxorubicin, paclitaxel |
SCRS HIPEC: Cisplatin+doxorubicin, paclitaxel |
17 |
| Woelber [19] | 2010 | Germany | 1996–2004 | Retrospective cohort study | 222 | 174 (78.3) | 48 (21.7) | Radical CRS | Radical CRS | 16 |
| Muñoz-Casares FC [20] | 2016 | Spain | 1996–2012 | Retrospective cohort study | 218 | 124 (56.6) | 94 (44.4) | PCRS+4–8cycles of carboplatin+paclitaxel neoadjuvant chemotherapy | SCRS 4–8cycles of carboplatin+paclitaxel neoadjuvant chemotherapy | 16 |
| Manzendo [21] | 2017 | Spain | 2007–2014 | Retrospective cohort study | 61 | 31 (51) | 30 (49) | PRCS+HIPEC | SCRS+HIPEC | 15 |
PCRS, primary cytoreductive surgery; SCRS, secondary cytoreductive surgery; HIPEC, Hyperthermic IntraPEritoneal Chemotherapy.